Skip navigation

Stay Ahead of Impactful Changes to Your Medicare Strategy

August 21, 2018
  • Arlington, VA

CBI’s Bio/Pharma Forum on The State of Medicare Reform is focused on the current healthcare landscape and proposed changes for Medicare. It is critical that pharmaceutical and biotech manufacturers keep abreast of how the changing healthcare and insurance landscape will impact Medicare strategy.

Attend this elite meeting to stay on the cutting-edge of information related to Medicare Part B and D and gain an early outlook to understand the major impact of the proposed changes.

Critical Topics for Discussion Include:

  • Discuss the overview of proposed legislative changes to Medicare Part B and D
  • Gain an update from Washington on the
    ripple effect of Medicare reform
  • Address the proposal to share drug rebates more
    directly with patients at the point of sale
  • Hear how plans review medicare rebates and bids
  • Discuss the potential impact of transitioning
    Medicare Part B covered drugs to Part D
  • Assess the recent changes to Medicare’s payment rate for certain Medicare Part B drugs purchased through the 340B program
  • Learn about the industry perception of co-pay accumulator programs for specialty drugs

Bio/Pharma Forum on The State of Medicare Reform

Stay Ahead of Impactful Changes to Your Medicare Strategy

CBI’s Bio/Pharma Forum on The State of Medicare Reform is focused on the current healthcare landscape and proposed changes for Medicare. It is critical that pharmaceutical and biotech manufacturers keep abreast of how the changing healthcare and insurance landscape will impact Medicare strategy.

Attend this elite meeting to stay on the cutting-edge of information related to Medicare Part B and D and gain an early outlook to understand the major impact of the proposed changes.

Critical Topics for Discussion Include:

  • Discuss the overview of proposed legislative changes to Medicare Part B and D
  • Gain an update from Washington on the
    ripple effect of Medicare reform
  • Address the proposal to share drug rebates more
    directly with patients at the point of sale
  • Hear how plans review medicare rebates and bids
  • Discuss the potential impact of transitioning
    Medicare Part B covered drugs to Part D
  • Assess the recent changes to Medicare’s payment rate for certain Medicare Part B drugs purchased through the 340B program
  • Learn about the industry perception of co-pay accumulator programs for specialty drugs